JP2017534419A - 呼吸器疾患のエアロゾル療法において使用するための吸入装置 - Google Patents
呼吸器疾患のエアロゾル療法において使用するための吸入装置 Download PDFInfo
- Publication number
- JP2017534419A JP2017534419A JP2017538457A JP2017538457A JP2017534419A JP 2017534419 A JP2017534419 A JP 2017534419A JP 2017538457 A JP2017538457 A JP 2017538457A JP 2017538457 A JP2017538457 A JP 2017538457A JP 2017534419 A JP2017534419 A JP 2017534419A
- Authority
- JP
- Japan
- Prior art keywords
- flow path
- aerosol
- gas
- inlet opening
- inhalation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000443 aerosol Substances 0.000 title claims abstract description 152
- 208000023504 respiratory system disease Diseases 0.000 title description 9
- 238000002560 therapeutic procedure Methods 0.000 title description 7
- 239000007789 gas Substances 0.000 claims abstract description 138
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 31
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000001301 oxygen Substances 0.000 claims abstract description 23
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 23
- 108060003951 Immunoglobulin Proteins 0.000 claims description 52
- 102000018358 immunoglobulin Human genes 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 33
- 229940124630 bronchodilator Drugs 0.000 claims description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
- 229920001184 polypeptide Polymers 0.000 claims description 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 26
- 239000003570 air Substances 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 17
- 238000011144 upstream manufacturing Methods 0.000 claims description 17
- 239000000168 bronchodilator agent Substances 0.000 claims description 12
- 206010024971 Lower respiratory tract infections Diseases 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 210000002345 respiratory system Anatomy 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 7
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims description 7
- 239000000812 cholinergic antagonist Substances 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical group CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 229960002052 salbutamol Drugs 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 5
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 4
- 239000001307 helium Substances 0.000 claims description 4
- 229910052734 helium Inorganic materials 0.000 claims description 4
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 229960000195 terbutaline Drugs 0.000 claims description 4
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 claims description 3
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims description 3
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 229960001334 corticosteroids Drugs 0.000 claims description 3
- 229960001022 fenoterol Drugs 0.000 claims description 3
- 229960002848 formoterol Drugs 0.000 claims description 3
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical group C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 3
- 229960001361 ipratropium bromide Drugs 0.000 claims description 3
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims description 3
- 229960000797 oxitropium Drugs 0.000 claims description 3
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 claims description 3
- 229960004017 salmeterol Drugs 0.000 claims description 3
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical group O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims description 3
- 229940110309 tiotropium Drugs 0.000 claims description 3
- 229960000859 tulobuterol Drugs 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 10
- 230000000712 assembly Effects 0.000 abstract 1
- 238000000429 assembly Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 22
- 239000000427 antigen Substances 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 21
- 229940079593 drug Drugs 0.000 description 21
- 150000001413 amino acids Chemical group 0.000 description 18
- 241000725643 Respiratory syncytial virus Species 0.000 description 16
- 239000012634 fragment Substances 0.000 description 12
- 238000002664 inhalation therapy Methods 0.000 description 12
- 239000006199 nebulizer Substances 0.000 description 12
- 230000008021 deposition Effects 0.000 description 11
- 239000003365 glass fiber Substances 0.000 description 10
- 230000029058 respiratory gaseous exchange Effects 0.000 description 10
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- 230000000241 respiratory effect Effects 0.000 description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 241000711920 Human orthopneumovirus Species 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- -1 pyrbuterol Chemical compound 0.000 description 6
- 125000006850 spacer group Chemical group 0.000 description 6
- 201000003883 Cystic fibrosis Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 206010006448 Bronchiolitis Diseases 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 206010014561 Emphysema Diseases 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000005279 Status Asthmaticus Diseases 0.000 description 3
- 238000000889 atomisation Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000002663 nebulization Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241000238578 Daphnia Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001503699 Muscovy duck parvovirus Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000035565 breathing frequency Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 108700023453 human respiratory syncytial virus F Proteins 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229960001268 isoetarine Drugs 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- SYHGEUNFJIGTRX-UHFFFAOYSA-N methylenedioxypyrovalerone Chemical compound C=1C=C2OCOC2=CC=1C(=O)C(CCC)N1CCCC1 SYHGEUNFJIGTRX-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 229950003941 racepinefrine Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000024584 respiratory abnormality Diseases 0.000 description 1
- 229960001634 ritodrine Drugs 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 229940036185 synagis Drugs 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A61M11/003—Particle size control by passing the aerosol trough sieves or filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
- A61M11/042—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0085—Inhalators using ultrasonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0091—Inhalators mechanically breath-triggered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/02—Inhalators with activated or ionised fluids, e.g. electrohydrodynamic [EHD] or electrostatic devices; Ozone-inhalators with radioactive tagged particles
- A61M15/025—Bubble jet droplet ejection devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
- A61M16/201—Controlled valves
- A61M16/202—Controlled valves electrically actuated
- A61M16/203—Proportional
- A61M16/204—Proportional used for inhalation control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
- A61M16/201—Controlled valves
- A61M16/202—Controlled valves electrically actuated
- A61M16/203—Proportional
- A61M16/205—Proportional used for exhalation control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
- A61M16/208—Non-controlled one-way valves, e.g. exhalation, check, pop-off non-rebreathing valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0208—Oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/025—Helium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0266—Nitrogen (N)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/11—Laminar flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2240/00—Specially adapted for neonatal use
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mechanical Engineering (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本明細書で使用される以下の表現は、説明が特定の場合において異なる意味を提供する場合を除き、この説明において、通常は概説であると解釈されなければならない。
吸入された薬物量について、空気の供給がある状態とない状態とにおいてシミュレーションされた吸入とエアロゾル投与との効果を評価する実験において、配列番号:71(Table A-3(表4))が使用された。
1)追加的な空気供給なし。ガス入口開口が開口される。
2)追加的な空気供給なし。ガス入口開口が遮断される。
3)ガス入口開口を介して2L/分で追加的な空気供給あり。
101 エアロゾル生成器
102 振動可能ふるい、振動ふるい
103 容器
104 ガス入口開口
105 顔マスク
106 ケーシング
107 エアロゾル入口開口
108 患者接触面
109 弁(1方向呼出または2方向吸入/呼出弁)
110 流路、混合路
111 横開口
112 スイッチ
113 管継手
114 蓋
115 キーロック
116 USBポート
117 開口、孔
118 基体ユニット
119 混合路ユニット
200 SAINTモデル
201 SAINTモデルの顔/喉部
202 SAINTモデルの鼻部
300 ガラス繊維フィルタ組立体
Claims (28)
- (a)振動可能ふるいを含むエアロゾル生成器と、
(b)噴霧化される液体のための容器であって、前記振動可能ふるいと流体接続する容器と、
(c)ガス入口開口と、
(d)ケーシング、
エアロゾル入口開口、
患者接触面、および
0.5から5mbarの範囲から選択される呼出抵抗を有する前記ケーシング内の1方向呼出弁または2方向吸入/呼出弁
を含む、顔マスクと、
(e)前記ガス入口開口から前記顔マスクの前記エアロゾル入口開口まで延びた流路であって、
横開口であって、前記横開口を経て前記エアロゾル生成器が少なくとも部分的に前記流路内に挿入される、横開口、および
1から20L/分の流量において前記ガス入口開口と前記顔マスクの前記エアロゾル入口開口との間における一定の流れ抵抗
を含む、流路と、
を備える、患者に噴霧化エアロゾルを送達するための吸入装置。 - 前記流路が、前記横開口のすぐ上流の位置において、2L/分の流量において少なくとも4m/sの平均ガス速度を達成するように寸法決めされ、形作られ、および/または、
前記横開口の上流における前記流路は、ガスが1から20L/分の流量で前記流路を通って搬送されるときに層流をもたらすように形作られる、
請求項1に記載の吸入装置。 - 前記ガス入口開口が、管継手として形作られ、
前記流路が、好ましくは、ガスを受け入れるための別の入口開口を含まない、
請求項1または請求項2に記載の吸入装置。 - 前記エアロゾル生成器が、前記流路の長軸に対して約90°の角度で、前記流路内に噴霧化エアロゾルを放出するように向けられ、
前記吸入装置が、好ましくは、前記エアロゾル生成器の動作を開始および停止するためのスイッチを備え、
前記エアロゾル生成器の前記動作が、前記振動可能ふるいの継続振動を含む、
請求項1から請求項3のいずれか一項に記載の吸入装置。 - 前記顔マスクが、90mL以下、または70mL以下、または約50mL以下の公称内部容量をもつか、または、
前記公称内部容量が、患者の平均一回呼吸量より小さい、
請求項1から請求項4のいずれか一項に記載の吸入装置。 - 前記顔マスクが、両方向において3mbar以下の抵抗を有する2方向吸入呼出弁を含み、
前記顔マスクの公称内部容量が、約50mL以下である、
請求項1から請求項5のいずれか一項に記載の吸入装置。 - 前記横開口と前記顔マスクの前記エアロゾル入口開口との間における前記流路の内部容積が、30mL以下である、
請求項1から請求項6のいずれか一項に記載の吸入装置。 - 請求項1から請求項7のいずれか一項に記載の前記吸入装置と、1から5L/分の範囲内における一定の流量でガスを提供する前記ガス源と、を備え、
前記ガス源は、前記ガス入口開口を通して前記ガスが前記流路に入るように前記吸入装置に接続され、
前記ガスが、酸素、空気、酸素富化空気、酸素と窒素との混合物、およびヘリウムと酸素との混合物から選択される、
組立体。 - (a)請求項1から請求項7のいずれか一項に記載の前記吸入装置、または、請求項8に記載の前記組立体と、(b)吸入用法のための薬剤組成物と、
を備える、組み合わせまたはキット。 - 前記薬剤組成物は、抗生物質、抗ウイルス物質、気管支拡張薬、抗コリン作動薬、コルチコステロイド、高張食塩液、抗体、抗体断片、および免疫グロブリン単一可変領域から選択される活性薬を含む、
請求項9に記載の組み合わせまたはキット。 - 前記活性薬が、抗RSV剤であり、
前記抗RSV剤が、任意選択で、1つまたは複数の抗RSV免疫グロブリン単一可変領域を含むか、または、実質的に1つまたは複数の抗RSV免疫グロブリン単一可変領域からなるポリペプチドである、
請求項10に記載の組み合わせまたはキット。 - (a)前記抗RSV免疫グロブリン単一可変領域が、配列番号:46のアミノ酸配列を含むCDR1と、配列番号:49〜50の1つのアミノ酸配列を含むCDR2と、配列番号:61のアミノ酸配列を含むCDR3とを含み、
(b)前記抗RSV免疫グロブリン単一可変領域が、配列番号:1〜34のアミノ酸配列の1つから選択され、および/または、
(c)前記ポリペプチドが、配列番号:65〜85のアミノ酸配列の1つから選択される、
請求項11に記載の組み合わせまたはキット。 - (a)請求項1から請求項7のいずれか一項に記載の前記吸入装置を提供するステップと、
(b)ガス源を提供するステップと、
(c)1から5L/分の範囲内における一定の流量で、前記ガス入口開口を通してガスが前記流路に入るように、前記吸入装置に前記ガス源を接続するステップと、
を含む、患者に噴霧化エアロゾルを送達する方法。 - 前記呼吸器系に影響する疾患を患う患者の治療において使用するための、請求項1から請求項7のいずれか一項に記載の吸入装置、請求項8に記載の組立体、または請求項9から請求項12のいずれか一項に記載のキットもしくは組み合わせ。
- 前記患者が、
(a)新生児、乳児、幼児、または就学児などの小児患者、
(b)管理下の経口吸入が不可能であるか、またはかなり妨げられる成人患者、および/または、
(c)呼吸器感染症を患う患者であり、
前記呼吸器感染症が、任意選択で、RSV下気道感染症などのRSV感染症である、
請求項14の使用のための吸入装置、組立体、キットまたは組み合わせ。 - 前記振動可能ふるいが、1,000から4,000個の開口を備え、前記開口の最小直径が、主に、1.5から3.0μmの範囲内である、
請求項1から請求項7のいずれか一項に記載の吸入装置。 - 前記ガス入口開口を加圧されたガス源に接続したとき、前記流路を通るガスの流れを、1から5L/分の範囲内における一定の流量に制限することが可能な流量制限器をさらに備える、
請求項1から請求項7または請求項16のいずれか一項に記載の吸入装置。 - 前記エアロゾル生成器を制御するための電子制御装置、および
前記ガス入口開口を含む前記流路の上流部
を備える基体ユニットと、
前記横開口を含む前記流路の下流部
を備える混合路ユニットと、
を備え、
前記下流部が、前記流路が下流方向に広がる区域を備え、前記区域が、前記横開口の下流に配置される、
請求項1から請求項7または請求項16から請求項17のいずれか一項に記載の吸入装置。 - 前記患者が、小児患者であり、好ましくは、2歳以下である、
請求項9から請求項12のいずれか一項に記載の組み合わせまたはキット。 - 前記組み合わせまたはキットが、約1から2mg/体重kgの1日の投与量で前記抗RSV剤を投与する指示を含む、
請求項11、請求項12、または請求項19のいずれか一項に記載の組み合わせまたはキット。 - 気管支拡張薬をさらに含む、
請求項11、請求項12、請求項19、または請求項20のいずれか一項に記載の組み合わせまたはキット。 - 前記気管支拡張薬が、ベータ2ミメティックのクラスに属する、
請求項21に記載の組み合わせまたはキット。 - 前記気管支拡張薬が、長時間作用型ベータ2ミメティックのクラスに属する、
請求項22に記載の組み合わせまたはキット。 - 前記気管支拡張薬は、ホルモテロールまたはその溶媒和物、サルメテロールまたはその塩、および、その混合物から選択される、
請求項23に記載の組み合わせまたはキット。 - 前記気管支拡張薬が、短時間作用型ベータ2ミメティックのクラスに属する、
請求項22に記載の組み合わせまたはキット。 - 前記気管支拡張薬は、サルブタモール、テルブタリン、ピルブテロール、フェノテロール、ツロブテロール、レボサブタモール、およびその混合物から選択される、
請求項25に記載の組み合わせまたはキット。 - 前記気管支拡張薬が、抗コリン作動薬のクラスに属する、
請求項21に記載の組み合わせまたはキット。 - 前記気管支拡張薬は、チオトロピウム、オキシトロピウム、イプラトロピウム臭化物、および、その混合物から選択される、
請求項27に記載の組み合わせまたはキット。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462062469P | 2014-10-10 | 2014-10-10 | |
US62/062,469 | 2014-10-10 | ||
US201462067096P | 2014-10-22 | 2014-10-22 | |
US62/067,096 | 2014-10-22 | ||
US201462074842P | 2014-11-04 | 2014-11-04 | |
US62/074,842 | 2014-11-04 | ||
EP14193094 | 2014-11-13 | ||
EP14193094.1 | 2014-11-13 | ||
PCT/EP2015/073486 WO2016055655A1 (en) | 2014-10-10 | 2015-10-09 | Inhalation device for use in aerosol therapy of respiratory diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017534419A true JP2017534419A (ja) | 2017-11-24 |
JP6617151B2 JP6617151B2 (ja) | 2019-12-11 |
Family
ID=83280657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017538457A Active JP6617151B2 (ja) | 2014-10-10 | 2015-10-09 | 呼吸器疾患のエアロゾル療法において使用するための吸入装置 |
Country Status (17)
Country | Link |
---|---|
US (1) | US10512739B2 (ja) |
EP (1) | EP3204095B8 (ja) |
JP (1) | JP6617151B2 (ja) |
KR (1) | KR102364212B1 (ja) |
CN (1) | CN106999420B (ja) |
AU (1) | AU2015329935B2 (ja) |
CA (1) | CA2963030C (ja) |
DK (1) | DK3204095T3 (ja) |
ES (1) | ES2732837T3 (ja) |
HU (1) | HUE044199T2 (ja) |
PL (1) | PL3204095T3 (ja) |
PT (1) | PT3204095T (ja) |
RU (1) | RU2700650C2 (ja) |
SG (1) | SG11201702699TA (ja) |
SI (1) | SI3204095T1 (ja) |
TR (1) | TR201909589T4 (ja) |
WO (1) | WO2016055655A1 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017040391A1 (en) * | 2015-08-28 | 2017-03-09 | The Research Institute At Nationwide Children's Hospital | Interactive spacer for respiratory device |
AU2017259876A1 (en) | 2016-05-02 | 2018-10-25 | Ablynx Nv | Treatment of RSV infection |
WO2017192774A1 (en) * | 2016-05-03 | 2017-11-09 | Pneuma Respiratory, Inc. | Methods for the systemic delivery of therapeutic agents to the pulmonary system using a droplet delivery device |
PT3519025T (pt) * | 2016-09-30 | 2023-03-03 | De Motu Cordis Pty Ltd | Dispositivo de administração |
WO2018099968A1 (en) * | 2016-11-29 | 2018-06-07 | Ablynx N.V. | Treatment of infection by respiratory syncytial virus (rsv) |
WO2018213834A1 (en) | 2017-05-19 | 2018-11-22 | Pneuma Respiratory, Inc. | Dry powder delivery device and methods of use |
US11738158B2 (en) | 2017-10-04 | 2023-08-29 | Pneuma Respiratory, Inc. | Electronic breath actuated in-line droplet delivery device and methods of use |
US11458267B2 (en) | 2017-10-17 | 2022-10-04 | Pneuma Respiratory, Inc. | Nasal drug delivery apparatus and methods of use |
WO2019094628A1 (en) | 2017-11-08 | 2019-05-16 | Pneuma Respiratory, Inc. | Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use |
US20200016360A1 (en) | 2018-07-11 | 2020-01-16 | Martin Allan Morris | Low flow adaptor to deliver aerosols via nasal cannula without crashout |
CN112543962B (zh) * | 2018-08-09 | 2022-09-30 | 阿明·比达里亚·莫尼里 | 用于语言疗法、施用吸入药物以及用于治疗耳炎、鼻窦炎和气压伤的设备 |
US20220008666A1 (en) * | 2018-10-19 | 2022-01-13 | Vectura Delivery Devices Limited | Pharmaceutical administration to neonates, infants and children |
PL429292A1 (pl) * | 2019-03-17 | 2020-09-21 | Wiśniewski Jan | Maska przeciwpyłowa |
US20220176064A1 (en) * | 2019-04-12 | 2022-06-09 | Sensory Cloud, Llc | Thin-profile delivery apparatus and media cartridges |
US20220387736A1 (en) * | 2020-10-18 | 2022-12-08 | Medshield, Llc | Nebulizer system |
TWI779663B (zh) * | 2021-06-15 | 2022-10-01 | 岩成科技事業股份有限公司 | 震盪式吐氣正壓裝置 |
KR20240037245A (ko) | 2021-06-22 | 2024-03-21 | 뉴마 레스퍼러토리 인코포레이티드 | 푸시 이젝션에 의한 액적 전달 장치 |
CN113952320B (zh) * | 2021-09-18 | 2022-03-18 | 健康元药业集团股份有限公司 | 一种包含妥布霉素吸入溶液的药物组件及其用途 |
US11944742B1 (en) * | 2023-06-08 | 2024-04-02 | Microneb Tech Holdings, Inc. | Apparatus, methods, and systems for administering a medication to an animal |
US11925748B1 (en) * | 2023-06-08 | 2024-03-12 | Microneb Tech Holdings, Inc. | Apparatus, methods, and systems for administering a medication to a patient from a capsule using an atomizer |
US11850356B1 (en) * | 2023-06-08 | 2023-12-26 | Microneb Tech Holdings, Inc. | Apparatus, methods, and systems for administering a medication to a patient from a capsule using an atomizer |
US11844900B1 (en) * | 2023-06-08 | 2023-12-19 | Microneb Tech Holdings, Inc. | Apparatus, methods, and systems for administering a medication to a patient from a capsule using an atomizer |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007531577A (ja) * | 2004-04-02 | 2007-11-08 | アメリカ合衆国 | エアロゾル送達のシステムおよび方法 |
US20120318265A1 (en) * | 2011-06-17 | 2012-12-20 | Nostrum Technology Llc | Mask for the administration of inhaled drugs |
WO2013132056A1 (en) * | 2012-03-09 | 2013-09-12 | Activaero Gmbh | Mixing channel for an inhalation device and inhalation device |
JP2014083446A (ja) * | 2012-10-26 | 2014-05-12 | Activaero Gmbh | 吸入装置 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4430995A (en) * | 1981-05-29 | 1984-02-14 | Hilton Joseph R | Power assisted air-purifying respirators |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
PT656946E (pt) | 1992-08-21 | 2001-12-28 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
IL137963A0 (en) | 1998-02-19 | 2001-10-31 | Xcyte Teherapies Inc | Compositions and methods for regulating lymphocyte activation |
SE9902627D0 (sv) * | 1999-07-08 | 1999-07-08 | Siemens Elema Ab | Medical nebulizer |
US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
EP1656128A4 (en) | 2003-08-12 | 2007-02-28 | William M Yarbrough | SINGLE ACNE TREATMENT AND METHOD OF USE |
GB0327723D0 (en) | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
WO2006059108A2 (en) | 2004-12-02 | 2006-06-08 | Domantis Limited | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES |
EP1695728A1 (de) * | 2005-02-23 | 2006-08-30 | Activaero GmbH | Bauteil für eine Inhalationsvorrichtung, Inhalationsvorrichtung mit diesem Bauteil und Steuerverfahren für ein solches Bauteil |
DE102005010965B3 (de) * | 2005-03-10 | 2006-08-03 | Medspray Xmems Bv | Inhalator mit einem Mischkanal zum Erzeugen eines zu inhalierenden Aerosols |
TW200740843A (en) | 2006-01-24 | 2007-11-01 | Domantis Ltd | Ligands that bind IL-4 and/or IL-13 |
DE102006006183A1 (de) * | 2006-02-10 | 2007-08-16 | Pari GmbH Spezialisten für effektive Inhalation | Inhalationstherapievorrichtung für die Anwendung bei Frühgeborenen und Kleinkindern |
US8225785B2 (en) * | 2006-10-03 | 2012-07-24 | Smiths Medical Asd, Inc. | Vibratory PEP therapy system with medicated aerosol nebulizer |
AU2008219216A1 (en) | 2007-02-21 | 2008-08-28 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
WO2008116165A2 (en) | 2007-03-21 | 2008-09-25 | Next Safety, Inc. | Methods and systems of delivering medication via inhalation |
NZ581097A (en) | 2007-05-24 | 2012-03-30 | Ablynx Nv | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
ES2452935T3 (es) * | 2008-04-04 | 2014-04-03 | Nektar Therapeutics | Dispositivo de aerosolización |
US8464715B2 (en) * | 2008-04-16 | 2013-06-18 | Stephen Donald Flynn, SR. | Multipurpose therapeutic face mask |
DE102008022987A1 (de) * | 2008-05-09 | 2009-11-12 | Pari Pharma Gmbh | Vernebler für Beatmungsmaschinen und Beatmungsmaschine mit einem solchen Vernebler |
WO2010065616A1 (en) * | 2008-12-02 | 2010-06-10 | Thermocure, Inc. | Systems and methods for delivery of a breathing gas with fine ice particles |
CA2753645C (en) * | 2009-02-27 | 2016-07-26 | Pari Pharma Gmbh | Method for operating an aerosol inhalation device and aerosol inhalation device |
RU2016103067A (ru) | 2009-06-05 | 2018-11-20 | Аблинкс Нв | Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей |
BR112012016540B1 (pt) | 2010-01-07 | 2020-03-24 | Koninklijke Philips N.V. | Aparelho de administração de medicamento respiratório e dispositivo de feedback e conformidade para uso com um dispositivo de armazenamento e administração de medicamento |
PT2533761T (pt) * | 2010-02-11 | 2019-06-17 | Ablynx Nv | Métodos e composições para a preparação de aerossóis |
US20130118485A1 (en) * | 2010-04-07 | 2013-05-16 | Kast Silicone Ltd. | Means and method for administering medicaments to infants |
KR20130117755A (ko) | 2010-06-21 | 2013-10-28 | 맨카인드 코포레이션 | 건조 분말 약물 운반 시스템 및 방법 |
WO2013067164A1 (en) | 2011-11-04 | 2013-05-10 | Discovery Laboratories, Inc. | Ventilation circuit adaptor and proximal aerosol delivery system |
US10046121B2 (en) | 2011-12-27 | 2018-08-14 | Vectura Gmbh | Inhalation device with feedback system |
TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒f蛋白質的人類抗體及其使用方法 |
CA2963037A1 (en) * | 2014-10-10 | 2016-04-14 | Ablynx N.V. | Treatment of rsv infection |
AU2017259876A1 (en) * | 2016-05-02 | 2018-10-25 | Ablynx Nv | Treatment of RSV infection |
WO2017192774A1 (en) * | 2016-05-03 | 2017-11-09 | Pneuma Respiratory, Inc. | Methods for the systemic delivery of therapeutic agents to the pulmonary system using a droplet delivery device |
-
2015
- 2015-10-09 TR TR2019/09589T patent/TR201909589T4/tr unknown
- 2015-10-09 HU HUE15778328 patent/HUE044199T2/hu unknown
- 2015-10-09 AU AU2015329935A patent/AU2015329935B2/en active Active
- 2015-10-09 KR KR1020177012510A patent/KR102364212B1/ko active IP Right Grant
- 2015-10-09 SI SI201530785T patent/SI3204095T1/sl unknown
- 2015-10-09 SG SG11201702699TA patent/SG11201702699TA/en unknown
- 2015-10-09 WO PCT/EP2015/073486 patent/WO2016055655A1/en active Application Filing
- 2015-10-09 DK DK15778328.3T patent/DK3204095T3/da active
- 2015-10-09 PL PL15778328T patent/PL3204095T3/pl unknown
- 2015-10-09 ES ES15778328T patent/ES2732837T3/es active Active
- 2015-10-09 CA CA2963030A patent/CA2963030C/en active Active
- 2015-10-09 CN CN201580054583.9A patent/CN106999420B/zh active Active
- 2015-10-09 RU RU2017115845A patent/RU2700650C2/ru active
- 2015-10-09 EP EP15778328.3A patent/EP3204095B8/en active Active
- 2015-10-09 US US15/517,579 patent/US10512739B2/en active Active
- 2015-10-09 JP JP2017538457A patent/JP6617151B2/ja active Active
- 2015-10-09 PT PT15778328T patent/PT3204095T/pt unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007531577A (ja) * | 2004-04-02 | 2007-11-08 | アメリカ合衆国 | エアロゾル送達のシステムおよび方法 |
US20120318265A1 (en) * | 2011-06-17 | 2012-12-20 | Nostrum Technology Llc | Mask for the administration of inhaled drugs |
WO2013132056A1 (en) * | 2012-03-09 | 2013-09-12 | Activaero Gmbh | Mixing channel for an inhalation device and inhalation device |
JP2014083446A (ja) * | 2012-10-26 | 2014-05-12 | Activaero Gmbh | 吸入装置 |
Also Published As
Publication number | Publication date |
---|---|
US10512739B2 (en) | 2019-12-24 |
KR102364212B1 (ko) | 2022-02-17 |
HUE044199T2 (hu) | 2019-10-28 |
JP6617151B2 (ja) | 2019-12-11 |
DK3204095T3 (da) | 2019-07-15 |
TR201909589T4 (tr) | 2019-07-22 |
EP3204095B1 (en) | 2019-05-29 |
WO2016055655A1 (en) | 2016-04-14 |
KR20170091087A (ko) | 2017-08-08 |
SG11201702699TA (en) | 2017-04-27 |
AU2015329935B2 (en) | 2019-09-19 |
CA2963030C (en) | 2021-07-13 |
CN106999420B (zh) | 2021-08-10 |
CN106999420A (zh) | 2017-08-01 |
EP3204095A1 (en) | 2017-08-16 |
RU2017115845A (ru) | 2018-11-13 |
ES2732837T3 (es) | 2019-11-26 |
US20170304565A1 (en) | 2017-10-26 |
AU2015329935A1 (en) | 2017-04-20 |
SI3204095T1 (sl) | 2019-08-30 |
RU2700650C2 (ru) | 2019-09-18 |
EP3204095B8 (en) | 2019-07-10 |
CA2963030A1 (en) | 2016-04-14 |
NZ730120A (en) | 2020-10-30 |
RU2017115845A3 (ja) | 2019-04-12 |
PL3204095T3 (pl) | 2019-10-31 |
PT3204095T (pt) | 2019-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6617151B2 (ja) | 呼吸器疾患のエアロゾル療法において使用するための吸入装置 | |
US8397713B2 (en) | Mouthpiece and flow rate controller for intrapulmonary delivery devices | |
Dolovich et al. | Aerosol drug delivery: developments in device design and clinical use | |
US20140147506A1 (en) | Delivery of Submicrometer and Nanometer Aerosols to the Lungs using Hygroscopic Excipients or Dual Stream Nasal Delivery | |
Schüepp et al. | In vitro determination of the optimal particle size for nebulized aerosol delivery to infants | |
KR20170093120A (ko) | Rsv 감염의 치료 방법 | |
WO2019115771A1 (en) | Nebuliser system, holding system, combination comprising nebuliser system and holding system, and aerosol administration method | |
WO2011125061A2 (en) | Means and method for administering medicaments to infants | |
Devadason | Recent advances in aerosol therapy for children with asthma | |
Fonceca et al. | Drug administration by inhalation in children | |
De Benedictis et al. | Use of inhaler devices in pediatric asthma | |
Laube et al. | ERS/ISAM task force consensus statement | |
CN109311968A (zh) | 治疗rsv感染 | |
WO2018099968A1 (en) | Treatment of infection by respiratory syncytial virus (rsv) | |
NZ730120B2 (en) | Inhalation device for use in aerosol therapy of respiratory diseases | |
Berger | Paediatric pulmonary drug delivery: considerations in asthma treatment | |
US20220118198A1 (en) | Mouthpiece and nebulizer having a mouthpiece | |
Panda | Inhalation Therapy in Children with Wheezing and Asthma: Spacer or Valved Holding Chamber (VHC) is an Optimal Drug Delivery System | |
Rubin et al. | 9 Inhalation Therapy in Infants and Children | |
Radic et al. | Medical aerosols: ins and outs of inhalation therapy | |
Flament | Pulmonary Drug Delivery to the Pediatric Population–A State‐of‐the‐Art Review | |
WO2006108563A1 (en) | Device for dry nebulization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170608 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180514 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190304 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190603 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191111 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6617151 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |